Chun-Hsu Pan1,2, Shu-Chen Chien2,3, Chang-Jui Chen2,3, Chun-Ming Shih4, Ming-Hsiung Hsieh5, Chun-Yao Huang4, Wei-Fung Bi4, Chao-Shun Chan4, Yung-Ta Kao4, Cheng-Yi Hsiao4, Shuo-Ju Chiang4, Kuang-Hsing Chiang4, Jen-Hung Huang5, Yun-Ru Liu6, Ji-Dung Luo7, Hui-Yu Huang8, Chieh-Hsi Wu9. 1. PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan. 2. School of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan. 3. Department of Pharmacy, Taipei Medical University Hospital, Taipei, 11031, Taiwan. 4. Department of Cardiology, Taipei Medical University Hospital, Taipei, 11031, Taiwan. 5. Department of Cardiology, Taipei Municipal Wanfang Hospital, Taipei Medical University, Taipei, 11031, Taiwan. 6. Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, 11031, Taiwan. 7. Bioinformatics Resource Center, The Rockefeller University, New York, NY, 10065, USA. 8. Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, 11031, Taiwan. 9. School of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan. chhswu@tmu.edu.tw.
Abstract
BACKGROUND: Patients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR). To date, no predictable biomarker can be applied in the clinic. MicroRNAs (miRNAs or miRs) play critical roles in transcription regulation, and their circulating levels were reported to have potential as clinical biomarkers. METHODS: In total, 93 coronary stent-implanted patients without pregnancy, liver or renal dysfunction, malignancy, hemophilia, or autoimmune diseases were recruited in this clinical study. All recruited participants were divided into an ISR group (n = 45) and a non-ISR group (n = 48) based on their restenotic status as confirmed by cardiologists at the first follow-up visit (6 months after surgery). Blood samples of all participants were harvested to measure circulating levels of miRNA candidates (miR-132, miR-142-5p, miR-15b, miR-24-2, and miR-424) to evaluate whether these circulating miRNAs can be applied as predictive biomarkers of ISR. RESULTS: Our data indicated that circulating levels of miR-142-5p were significantly higher in the ISR population, and results from the receiver operating characteristic (ROC) curve analysis also demonstrated superior discriminatory ability of miR-142-5p in predicting patients' restenotic status. In addition, circulating levels of miR-15b, miR-24-2, and miR-424 had differential expressions in participants with diabetes, hyperlipidemia, and hypertension, respectively. CONCLUSIONS: The current study revealed that the circulating level of miR-142-5p has potential application as a clinical biomarker for predicting the development of ISR in stent-implanted patients.
BACKGROUND:Patients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR). To date, no predictable biomarker can be applied in the clinic. MicroRNAs (miRNAs or miRs) play critical roles in transcription regulation, and their circulating levels were reported to have potential as clinical biomarkers. METHODS: In total, 93 coronary stent-implanted patients without pregnancy, liver or renal dysfunction, malignancy, hemophilia, or autoimmune diseases were recruited in this clinical study. All recruited participants were divided into an ISR group (n = 45) and a non-ISR group (n = 48) based on their restenotic status as confirmed by cardiologists at the first follow-up visit (6 months after surgery). Blood samples of all participants were harvested to measure circulating levels of miRNA candidates (miR-132, miR-142-5p, miR-15b, miR-24-2, and miR-424) to evaluate whether these circulating miRNAs can be applied as predictive biomarkers of ISR. RESULTS: Our data indicated that circulating levels of miR-142-5p were significantly higher in the ISR population, and results from the receiver operating characteristic (ROC) curve analysis also demonstrated superior discriminatory ability of miR-142-5p in predicting patients' restenotic status. In addition, circulating levels of miR-15b, miR-24-2, and miR-424 had differential expressions in participants with diabetes, hyperlipidemia, and hypertension, respectively. CONCLUSIONS: The current study revealed that the circulating level of miR-142-5p has potential application as a clinical biomarker for predicting the development of ISR in stent-implanted patients.
Authors: Teodora Barbalata; Alina I Scarlatescu; Gabriela M Sanda; Laura Toma; Camelia S Stancu; Maria Dorobantu; Miruna M Micheu; Anca V Sima; Loredan S Niculescu Journal: Int J Mol Sci Date: 2022-09-01 Impact factor: 6.208